PCRX — Pacira Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $1.22bn
- $1.46bn
- $674.98m
- 97
- 68
- 38
- 76
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 421 | 430 | 542 | 667 | 675 |
Cost of Revenue | |||||
Gross Profit | 314 | 312 | 401 | 468 | 490 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 411 | 391 | 452 | 607 | 604 |
Operating Profit | 10.5 | 38.3 | 89.9 | 60 | 70.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10.7 | 20.1 | 56.4 | 13.3 | 61.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11 | 146 | 42 | 15.9 | 42 |
Net Income Before Extraordinary Items | |||||
Net Income | -11 | 146 | 42 | 15.9 | 42 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -11 | 146 | 42 | 15.9 | 46.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.13 | 3.66 | 1.62 | 0.494 | 1.1 |